Breast Carcinoma Pathology — In Situ and Invasive

Multistep carcinogenesis and field effect

• Breast cancer develops through a field effect of cumulative genetic alterations affecting normal epithelium, progressing through atypical hyperplasia → in situ carcinoma → invasive carcinoma
• Early lesions including atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH) represent increased risk; DCIS and LCIS represent true malignant transformation with high-grade nuclear atypia
• Loss of myoepithelial layer (evident on p63, smooth muscle actin immunostains) distinguishes invasive from in situ disease—the defining feature in situ disease retains intact myoepithelial cells between malignant epithelium and basement membrane

Molecular pathogenesis

• Luminal A tumors (60-70%): ER/PR-positive, HER2-negative, low-grade, driven by PIK3CA mutations and CDH1 loss in ILC; superior prognosis
• Luminal B tumors: ER-positive, HER2-positive or high-grade, driven by CCND1 amplification and TP53 mutations; intermediate prognosis
• HER2-enriched tumors (15-20%): HER2-amplification (chromosome 17, typically detected by FISH or immunohistochemistry [IHC] 3+), TP53 mutations common; aggressive but responsive to trastuzumab
• Triple-negative/basal-like tumors (15-20%): ER/PR-negative, HER2-negative, high TP53 mutation rate, BRCA1/2 alterations, high mitotic rate; poorest prognosis, chemotherapy-dependent
• PTEN loss and RB pathway inactivation drive progression; E-cadherin (CDH1) mutations are specific to ILC, explaining discohesive growth pattern

Structural progression and invasion

• DCIS shows necrosis in ducts (comedonecrosis in high-grade), micropapillary or cribriform architectural patterns, nuclear pleomorphism; malignant cells remain confined by myoepithelium and basement membrane
• LCIS exhibits loss of E-cadherin (CDH1) leading to single-file growth pattern and loss of cellular cohesion; cells appear bland compared to DCIS despite malignant potential
• Invasion requires degradation of basement membrane via metalloproteinases (MMP-2, MMP-9), upregulation of angiogenic factors (VEGF), and epithelial-mesenchymal transition (EMT) with loss of E-cadherin and gain of N-cadherin and vimentin
• Sentinel lymph node metastasis occurs via lymphatic invasion; distant metastasis (bone 73%, lung 21%, liver 5%, brain 5%) via hematogenous spread

Non-modifiable factors

• Female sex and age: 99% of cases in women; incidence increases with age (median age 62 years at diagnosis)
• Genetic predisposition: BRCA1 mutations (lifetime risk 45-87%), BRCA2 mutations (45-69%), account for 5-10% of all breast cancers; PTEN mutations (Cowden syndrome), TP53 mutations (Li-Fraumeni), CHEK2, PALB2, ATM mutations confer increased risk
• Personal history: Prior breast cancer increases ipsilateral recurrence and contralateral breast cancer risk; atypical hyperplasia (ADH, ALH) increases risk 4-5 fold

Modifiable risk factors

• Reproductive and hormonal factors: Early menarche (before age 12), late menopause (after age 55), nulliparity, late first pregnancy (after age 30), short breastfeeding duration—all increase cumulative estrogen exposure
• Hormone replacement therapy (HRT): Increases risk particularly for current/recent use of combined estrogen-progestin HRT; tamoxifen increases endometrial cancer risk but reduces contralateral breast cancer risk
• Obesity and alcohol: Obesity in postmenopausal women increases risk via increased aromatase activity in adipose tissue; alcohol consumption (≥2 drinks/day) increases risk
• Prior thoracic radiation: Mantle field radiation for Hodgkin lymphoma markedly increases risk; latency period 10-20 years

In situ disease (DCIS and LCIS)

• Asymptomatic: Typically detected on screening mammography as microcalcifications or architectural distortion; LCIS often incidental finding
• No palpable mass: Usually impalpable; size ranges from <1 mm to several centimeters
• Mammographic findings: DCIS shows linear, branching, clustered microcalcifications (high suspicion for malignancy); LCIS typically non-calcifying, may show subtle density

Invasive carcinoma—early stage

• Palpable mass (most common, 75%): Hard, fixed, irregular borders; typically 1-3 cm at presentation
• Skin changes: Dimpling, peau d'orange (skin edema from lymphatic invasion), nipple retraction or discharge (if subareolar involvement), erythema (if inflammatory carcinoma)
• Axillary lymphadenopathy: Regional lymph node involvement in 40-50% at presentation (staging determines treatment intensity)

Advanced/locally advanced disease

• Large mass (>5 cm), skin ulceration, fixation to chest wall
• Inflammatory breast cancer: Rapid onset of breast erythema, edema, skin thickening (biopsy-proven dermal lymphatic invasion); IBC has 5-year survival ~40% versus ~90% for stage I-II

Metastatic disease manifestations

• Bone metastases: Back/skeletal pain, pathologic fractures (most common site)
• Pulmonary metastases: Dyspnea, cough (often asymptomatic on imaging)
• Hepatic metastases: Right upper quadrant pain, jaundice, elevated liver enzymes
• CNS metastases: Headache, neurological deficits, seizures; HER2+ and triple-negative tumors at higher risk

Histological findings—In Situ Lesions

Ductal Carcinoma In Situ (DCIS)

• Architecture: Fills and distends ducts; subtypes include cribriform (regular punched-out spaces), micropapillary (small papillary projections), solid (completely filling ducts), comedo (central necrosis with cell debris)
• Comedo-type DCIS (high-grade): Central comedonecrosis, high nuclear grade (G3), marked pleomorphism; higher risk of recurrence
• Non-comedo DCIS (low/intermediate-grade): Absence of necrosis, lower nuclear grade, better prognosis
• Nuclear features: Grade 1-3; high-grade DCIS shows marked pleomorphism, high mitotic rate, irregular chromatin
• Key feature: Intact myoepithelial layer (highlighted by p63, SMA immunostains) and preserved basement membrane = definition of "in situ" (not invasive)
• Microcalcifications: Calcium deposition in necrotic material (comedo) or within epithelial cells

Lobular Carcinoma In Situ (LCIS)

• Architecture: Single-file growth pattern, loss of cellular cohesion (E-cadherin loss), cells fill terminal duct-lobular units (TDLUs) without expanding ducts
• Cytology: Relatively bland nuclei (usually low-grade cytologically despite malignant behavior), small inconspicuous nucleoli, sparse mitoses
• E-cadherin IHC: Negative (pathognomonic, defining feature); ER typically positive
• No myoepithelial layer disruption visible on H&E but myoepithelium intact; some debate about LCIS classification (carcinoma vs. high-risk lesion)
• Incidental finding: Often found with DCIS or IDC; 20-25% develop contralateral breast cancer

Invasive Lesions

Invasive Ductal Carcinoma (IDC), No Special Type (NST)

• Architecture: Loss of normal glandular structure, clusters and nests of malignant cells in desmoplastic stromal response
• Myoepithelial loss: Absent myoepithelial cells (p63 negative), irregular infiltration through basement membrane into adipose tissue and stroma
• Cytology: Variable nuclear grade; IDC-NST encompasses majority (70-75%) of breast cancers
• Desmoplasia: Pronounced fibroblastic stromal response (hyperplasia of fibrous tissue around tumor), contributes to firm consistency

Invasive Lobular Carcinoma (ILC)

• Architecture: Infiltrating single cells and files (E-cadherin negative), lack of cohesion, often subtle infiltration making margin assessment difficult
• Cell morphology: Small cuboidal cells, targetoid pattern (eccentric nuclei), intracytoplasmic mucin vacuoles may be present
• Prognosis: Similar to grade-matched IDC; higher incidence of multiplicity and bilaterality; more difficult to detect mammographically

• Tubular carcinoma: Well-formed tubules, low nuclear grade, excellent prognosis (10-year survival ~90%)
• Mucinous (colloid) carcinoma: Gelatinous appearance, tumor cells floating in lakes of mucin, low-grade, excellent prognosis
• Papillary carcinoma: Prominent papillary architecture, usually low-grade
• Medullary carcinoma: Circumscribed mass, pushing margins, high nuclear grade BUT paradoxically better prognosis

Inflammatory Breast Cancer

• Diagnostic requirement: Dermal lymphatic invasion by malignant cells, clinical erythema/edema affecting >1/3 of breast skin
• Aggressive behavior, poor prognosis (5-year survival ~40%)

Gross pathology

• Cut surface: Firm to hard, tan-white, with infiltrative borders and central area of retraction/dimpling; IDC typically shows gritty texture from desmoplasia
• Comedo carcinoma: Gray-white central necrotic material expressible from ducts
• ILC: Often subtle, may appear as unremarkable fibrosis without obvious mass
• Size measurement: Document greatest dimension for TNM staging; absence of gross in situ component may indicate poor prognosis

Immunohistochemistry (IHC) panel

• ER/PR: Performed on all invasive carcinomas; ≥1% nuclear staining = positive (Allred score ≥2 or H-score system); 65-70% ER+, 50-60% PR+
• HER2: IHC 0-3+ (0/1+ negative, 2+ equivocal requiring FISH, 3+ positive); FISH shows HER2/CEP17 ratio ≥2.0 or average HER2 copy ≥6.0 = amplified; 15-20% HER2+
• Ki-67: Proliferation index ≥30% associated with higher grade, more aggressive behavior
• p63/SMA: Myoepithelial markers—positive in in situ lesions, negative in invasive disease
• E-cadherin: Negative in ILC (and often LCIS) due to CDH1 mutations; positive in IDC
• CK5/6, EGFR: Basal markers; positive in triple-negative/basal-like carcinomas
• Triple-negative definition: ER negative (<1%), PR negative (<1%), HER2 negative (IHC 0-1+ or FISH non-amplified)

Staging and grading

• Nottingham/Bloom-Richardson histological grade (G1-G3): Based on tubule formation (1-3 points), nuclear pleomorphism (1-3 points), mitotic rate (1-3 points); score 3-5=G1, 6-7=G2, 8-9=G3; prognostic significance independent of stage
• TNM staging (8th edition):
• T (tumor): T1a ≤0.5 cm, T1b 0.5-1 cm, T1c 1-2 cm, T2 >2-5 cm, T3 >5 cm, T4 skin/chest wall involvement
• N (nodes): N0 no nodes, N1 1-3 axillary nodes, N2 4-9 nodes or fixed/matted nodes, N3 ≥10 nodes or apical/supraclavicular nodes
• M (metastasis): M0 no distant metastases, M1 distant metastases present
• Stage grouping: Stage IA (T1, N0, M0), IB (T0-1, N1mi, M0), IIA (T0-1, N1; T2, N0), IIB (T2, N1; T3, N0), IIIA (T0-2, N2; T3, N1-2), IIIB (T4, N0-2), IIIC (any T, N3), IV (M1)
• Genomic grade index/Oncotype DX: 21-gene recurrence score for ER+ HER2- tumors; predicts risk of distant recurrence and benefit of chemotherapy

Laboratory and imaging findings

• Tumor markers (limited utility): CA 15-3, CEA may be elevated in metastatic disease but not useful for screening or diagnosis
• Mammography: Detects 80-90% of lesions; DCIS appears as microcalcifications (pleomorphic, linear, branching), IDC as irregular mass with spiculated margins
• Ultrasound: Helpful for distinguishing cystic from solid lesions; ILC may appear sonographically subtle
• MRI: Higher sensitivity (90-95%) but lower specificity; useful for assessing contralateral breast, detecting multifocal disease, and evaluating extent of disease in dense breasts
• Biopsy confirmation: Core needle biopsy (14G or larger) is standard; histology is gold standard for diagnosis and ER/PR/HER2 assessment

In Situ Disease (DCIS)

• Surgical excision: Breast-conserving therapy (BCT) with wide local excision (lumpectomy) with adequate margins (typically ≥2 mm) is standard; total mastectomy reserved for extensive/multifocal disease or patient preference
• Radiation therapy: Whole breast radiation following lumpectomy reduces recurrence (both DCIS and IDC) by ~50%; improves local control but does NOT improve overall survival; consider omitting in low-risk DCIS (small, low-grade, favorable margins, older patients)
• Endocrine therapy: Tamoxifen (5 years) reduces recurrence by ~30-50% in ER+ DCIS; aromatase inhibitors (AIs) alternative in postmenopausal women; consider

Complications of the disease

• Malignant spinal cord compression (emergency): vertebral metastases expand into the epidural space; signaled by progressive back pain worse when recumbent, then weakness, sensory level, and late bowel/bladder dysfunction. NCCN supportive-care guidance is immediate high-dose corticosteroid (dexamethasone) plus emergent whole-spine MRI — do not wait for plain films or for neurologic deficit to declare itself.
• Hypercalcemia of malignancy (emergency): osteolytic bone metastases and PTHrP drive calcium release; polyuria, constipation, confusion, short QT. Treated with isotonic saline volume repletion plus a bisphosphonate or denosumab (bone-modifying agents per ASCO/NCCN).
• Pathologic fracture and bone pain: lytic/mixed lesions in vertebrae, ribs, proximal femur — the most common metastatic site.
• Brain metastases with raised intracranial pressure (emergency): disproportionately HER2-positive and triple-negative disease; headache, seizure, focal deficit.
• Leptomeningeal carcinomatosis: classically over-represented in invasive lobular carcinoma; multifocal cranial neuropathies with normal CT — diagnosis is MRI plus CSF cytology.
• Dermal lymphatic obstruction: peau d'orange, skin ulceration, chest-wall fixation; malignant pleural effusion causes dyspnea.

Complications of treatment

• Lymphedema after axillary lymph node dissection: interruption of lymphatic drainage; arm heaviness and non-pitting swelling. Chronic lymphedema is the substrate for Stewart–Treves syndrome — cutaneous angiosarcoma appearing as violaceous nodules years later.
• Anthracycline cardiomyopathy: cumulative, dose-dependent, largely irreversible free-radical myocyte injury; falling LVEF on surveillance echocardiography.
• Trastuzumab cardiotoxicity: HER2 blockade in cardiomyocytes; typically reversible and not dose-dependent — ASCO cardiac dysfunction guidance calls for baseline and serial LVEF assessment.
• Tamoxifen: partial estrogen agonism in the endometrium causes endometrial hyperplasia/carcinoma (postmenopausal bleeding is the red flag) and venous thromboembolism.
• Aromatase inhibitors: estrogen deprivation causes arthralgias and accelerated bone loss — DEXA monitoring.
• Radiation: pneumonitis, and long-latency secondary angiosarcoma of the irradiated breast.
• Upstaging: DCIS on core biopsy harbors occult invasion in a substantial minority found at excision.

• E-cadherin is the single most tested stain: loss of CDH1 → discohesive single-file (Indian file) cells = lobular (LCIS/ILC). E-cadherin positive with cohesive nests = ductal. This one immunostain resolves most breast histology vignettes.
• Myoepithelium defines "in situ": p63/smooth muscle actin–positive cells surrounding malignant epithelium = in situ; their absence = invasion. A stem describing "cells breaching the basement membrane into desmoplastic stroma" is invasive by definition.
• LCIS is a bilateral risk marker, not a targeted lesion: it is typically non-calcifying, mammographically occult, and confers elevated risk in both breasts. Distractor to avoid — LCIS does not mandate re-excision to negative margins or mastectomy the way DCIS does; NCCN favors surveillance ± risk-reducing endocrine therapy.
• Eczematous, scaling, ulcerated nipple that does not respond to topical steroid = Paget disease of the breast. Large cells with clear halos and pale cytoplasm in the epidermis (mucin-positive, CK7-positive) reflect intraepidermal spread of an underlying DCIS or invasive carcinoma. Best next step: full-thickness nipple/skin punch biopsy plus diagnostic mammography — not a dermatology referral.
• **Erythema, edema and peau d'orange over a third or more of the breast = inflammatory carcinoma from dermal lymphatic invasion. It is a clinical** diagnosis confirmed by skin punch biopsy; the classic error is treating it as mastitis with antibiotics.
• Buzzwords by histology: comedonecrosis with linear/branching microcalcifications = high-grade DCIS; mucin lakes with floating cells = mucinous; well-formed angulated tubules = tubular; pushing borders with lymphoplasmacytic infiltrate = medullary (paradoxically favorable, BRCA1-associated).
• Receptors drive therapy, and menopausal status drives which endocrine agent: per NCCN, tamoxifen is appropriate in premenopausal women, whereas aromatase inhibitors require a postmenopausal state (or ovarian suppression) — a frequent distractor. ER/PR positivity is ≥1% nuclear staining (ASCO/CAP), and HER2 IHC 2+ must go to FISH before calling a tumor HER2-positive.